See today's BioWorld Asia
To read the full story, subscribe or sign in.

Chi-Med wins China approval for first in-house oncology drug

Jan. 5, 2021
By David Ho
No Comments
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) earned approval from China’s National Medical Products Administration (NMPA) for Sulanda (surufatinib) for the treatment of non-pancreatic neuroendocrine tumors (NETs).
BioWorld Asia Regulatory Cancer China NMPA